Janux Therapeutics, Inc.'s revenue has grown 46% a year over three years, and grown 95% a year over five. Revenue growth, 3-year annual rate: +46% (Biotechnology median +21%). Revenue growth, 5-year rate: +95%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2020 to FY2025, as filed.

JANXJanux Therapeutics, Inc.

Healthcare

$16.65-37% 1Y

$16.65

$12.1852 weeks$34.74

Is it growing?

Good

Revenue growing +5367% year on year. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Revenue trend+5367% in a yearSEC EDGAR · Jun 30, 2026

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +95% a year.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is JANX growing?

Janux Therapeutics, Inc.'s revenue has grown 46% a year over three years, and grown 95% a year over five.

+46%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +95%
Revenue growth, 5-year rate · +46% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›